现有和新兴的治疗选择对耐火性败血症休克:一个系统的审查
Flavio Eduardo Nacul1, Murilo Borges Bezerra2, Brenno Cardoso Gomes3
1Intensive Care Department, Pró-Cardíaco Hospital - Rio de Janeiro, Pró-Cardíaco Hospital, Rio de Janeiro 22280-003, Brazil.
World journal of critical care medicine
|December 11, 2025
概括
耐火性败血性休克的新兴疗法可能会改善血液动力学,但不会持续降低死亡率. 针对炎症的多模式方法对于更好的患者结果至关重要.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 耐火性败血性休克在重症监护机构中带来了重大挑战.
- 现有的耐火性败血症休克治疗方法有局限性.
研究的目的:
- 系统地审查对耐火性败血性休克新兴干预措施的随机对照试验 (RCT).
- 评估新型疗法对死亡率,血管压缩剂使用,ICU停留时间和器官功能障碍的影响.
主要方法:
- 从2000年到2024年,对主要数据库 (PubMed,EMBASE,Cochrane,Web of Science) 的系统文献搜索.
- 包括评估耐火性败血性休克创新疗法的RCT.
- 使用Cochrane风险偏差工具评估初级结果 (所有原因死亡率) 和二次结果 (ICU/住院长度,血管活性药物使用).
主要成果:
- 24个RCT评估了包括甲蓝,血管压素,压素和组合疗法 (皮,维生素C,胺) 在内的疗法.
- 死亡率的差异很大 (28.6%-56.8%). 甲蓝改善了无血管压缩剂的日子,terlipressin增强了输液.
- 虽然一些干预措施改善了器官功能 (例如,SOFA评分),但没有单一疗法显示出一致的生存益处.
结论:
- 辅助疗法可以改善耐火性败血性休克的血液动力稳定性和器官功能.
- 目前的证据并不总是显示新型干预措施降低了死亡率.
- 更大的试验和针对炎症的多模式策略是必要的,以改善结果.
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
580
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
580
01:22Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
01:24Blood Pressure Imbalances and Circulatory Shock
1.4K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
197
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
197
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
285
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
285
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
165
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
165